CytRx reports successful completion of phase I HIV Vaccine clinical trial
Data Indicates Favorable Safety and Immune Responses
DP6-001 was developed by researchers at University of Massachusetts Medical School (UMMS) and Advanced BioScience Laboratories (ABL), and exclusively licensed to CytRx. The vaccine initially "primes" the subject's immune system through the injection of DNA that causes the subject's own cells to produce the HIV "envelope" and "gag" proteins, followed by protein "boosts" from an injection that contains the corresponding HIV envelope proteins.
"We are very encouraged that analysis of the unblinded data confirms that DP6-001 is among the first experimental HIV vaccines to produce antibody responses with neutralizing activity against multiple HIV strains in humans," said Steven A. Kriegsman, President and CEO of CytRx. "The favorable priming of T- and B-cell immune responses to the vaccine also raises hope that this approach may produce a "memory" immune response that may be sufficiently robust to protect against the HIV virus over time."
DP6-001 is composed of a polyvalent DNA primer followed by a multivalent gp120 protein boost. The HIV vaccine formulation is based on multiple strains of HIV collected from infected people living in different parts of the world, representing five different strains of the virus. The vaccine contains elements from selected HIV genes, not the live virus, and therefore individuals receiving inoculations cannot get HIV from the vaccine.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.